Current clinical practice guidelines have identified a new category of heart failure: heart failure with improved ejection fraction.
Stopping medication for heart failure with improved ejection fraction
Current clinical practice guidelines have identified a new category of heart failure: heart failure with improved ejection fraction.
1,2 Multiple observational series on heart failure show improved measures of ventricular function after initial presentation of heart failure with reduced ejection fraction [3] [4] [5] [6] and improvement in clinical outcomes. What drives ventricular recovery is largely unknown; is it removal of insult (eg, tachycardia or toxins) or a fortuitous response to medical or device therapy? Moreover, the biology of true ventricular recovery, if such an effect occurs, is unknown. Prag matically, a salient question emerges: in patients with improved heart failure, is ongoing exposure to multidrug medical treatment still required?
In The Lancet, Brian P Halliday and colleagues 7 report the results of the TREDHF trial, an openlabel, pilot, randomised study of evidencebased medical treatment withdrawal for reduced ejection fraction heart failure due to dilated cardiomyopathy in patients with complete restoration of ventricular function (left ventricular ejection fraction [LVEF] >50%), normalisation of biomarker profiles (Nterminal proBtype natriuretic peptide [NTproBNP] <250 ng/L), and New York Heart Association Class class I symptoms. By use of an empirically derived protocol for medication withdrawal over 16 weeks, the investigators 7 identified a compelling 44% rate of recrudescent ventricular dysfunction represented by a drop in ejection fraction (in 11 of 25 patients randomly assigned to treatment withdrawal who met the primary endpoint of relapse compared with none of 26 assigned to continue treatment; Kaplan Meier estimate of event rate 45·7% [95% CI 28·5-67·2]; p=0·0001) and a rise in biomarkers over a followup period of 6 months. However, evidence of recrudescent heart failure-defined as a drop in LVEF of 10% to less than 50%, increase in left ventricular end diastolic volume by more than 10% or a twofold increase in NTproBNP to more than 400 ng/L, or clinical symptoms-became apparent within just 8 weeks. A similar incidence of recrudescent heart failure (in nine [36·0%] of 25 patients) was noted in the control group at the time of the single arm crossover; and the independent data safety monitor was alerted early in the study to a high occurrence of recurrent heart failure. The authors are acknowledged for addressing a provocative question, for acting expe ditiously to resume medical treatments before overt clinical decompensation, and for a priori creating a process to adjudicate events and terminate the trial as needed.
The key commentary, however, is the scientific implication of these results. First, we are reminded that mechanisms of improvement after exposure to evidence based medical treatments, although well informed, have not been fully resolved. Other than LVEF, there are no biomarkers or clinical profiles that align with treatment responses. We have no signal or barometer to suggest that a previously indicated treatment for reduced ejection fraction is no longer necessary and can be safely discontinued.
Second, we should be more precise with our nomenclature. Those patients who have restoration of ventricular function are less likely to have recovered ventricular function and more appropriately should be described as having ventricular dysfunction in remission. The parallels with oncology are appropriate. This distinction has been previously described in the literature 8 but the results of the TREDHF study now endorse the view that most patients with restoration of ventricular function as measured by an improved LVEF are in remission and have an indefinite indication for evidence based medical treatment without interruption.
Third, recovery would necessarily suggest that intrinsic contractility and especially cardiac mechanics, as assessed more precisely by Lagrangian strain, have been restored; protein expression has been normalised; and the neurohormonal milieu has returned to normal and is no longer activated. In fact, recent data show that many patients with restored ejection fraction still have underlying abnormal cardiac mechanics (ie, impaired longitudinal strain) and are at risk for clinical events and heart failure relapse, even with continued medical treatment. 9 Thus, we would expect that those who had recrudescent heart failure (44%) might have had abnormal strain and those who did not relapse (n=30) should have had intact strain measures. However, the reported strain measures as obtained by deformationtracking cardiovascular magnetic resonance (CMR) were in the normal range for most patients in TREDHF. Importantly, measurement of strain is not yet standardised. As a case in point, featuretracking CMR methods have much higher reported normal values (-0·19). 10 This uncertainty around restoration of cardiac mechanics in patients with restored ejection fraction emphasises the need for validated sequencespecific normal ranges for CMRderived strain methods and highlights the notion that true recovery of normal ventricular function is likely an infrequent occurrence. 9 Molecular pathways involved in fibrosis, 11 excitation-contraction coupling and calcium handling, 12 and Ttubule systems 13 might further define the extent of ventricular recovery. Certain genomics in dilated cardiomyopathy predict prognosis, risk of sudden death, and response to treatments. It is not surprising that almost a quarter of patients in this study had truncating variants in TTN, which tends to have a more benign course than other genetic cardiomyopathies (eg, LMNA). 14 The results of TREDHF are not definitive as this was a highly selected, openlabel pilot study with small numbers of patients with dilated cardiomyopathy; all of these aspects were necessary to ensure safety and restrict exposure to an uncertain intervention. Further studies to identify ventricular recovery are warranted, but we should tread lightly. In addition to the clinical findings from this study-the effects of advanced age, higher NTproBNP concentration, the need for a multidrug heart failure regimen, and reduced global radial strainfuture explorations should include a broader profile of omics (eg, proteomics, genomics, and metabolomics) and rigorously standardised measures of cardiac mechanics. For those in whom recovery has occurred, avoidance of morbidity and costs associated with lifelong medical treatment can and should matter. For those in remission, identifying the minimal exposure to evidence based medical treatment required for stability should be a similar pursuit.
Going forward, in response to a patient's question: "Now that my heart failure has improved, am I able to stop my heart failure drugs?", the answer should be, "No, not at this time." In those patients fortunate enough to have an improvement in ventricular function and amelioration of the clinical syndrome of heart failure, we should continue effective treatments indefinitely.
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